Dihydropyrimidine Dehydrogenase (DPD): Role, Deficiency, and Clinical Implications

- Advertisement -

Dihydropyrimidine dehydrogenase (DPD) is the initial and rate-limiting enzyme in the catabolism of pyrimidines, particularly uracil and thymine. Encoded by the DPYD gene, this enzyme plays a pivotal role not only in nucleotide homeostasis but also in the metabolism of several chemotherapeutic agents, most notably the fluoropyrimidines such as 5-fluorouracil (5-FU) and capecitabine.

From a clinical perspective, variations in DPD activity have profound implications for oncology. Deficiency of this enzyme—whether partial or complete—can result in severe and sometimes life-threatening toxicity in patients receiving fluoropyrimidine-based chemotherapy. Consequently, dihydropyrimidine dehydrogenase deficiency has emerged as a critical determinant in cancer pharmacogenomics and personalized medicine.

In this article, we will explore the molecular biology of DPD, the genetic and biochemical basis of DPD deficiency, its clinical relevance, and the strategies used to screen and manage patients at risk of fluoropyrimidine-related toxicities.

2. Molecular Biology of Dihydropyrimidine Dehydrogenase (DPD)

Dihydropyrimidine dehydrogenase (DPD) is a cytosolic flavoprotein enzyme that catalyzes the first and rate-limiting step of pyrimidine catabolism, converting uracil and thymine into their respective dihydro-derivatives. This enzymatic reaction is essential for maintaining nucleotide balance within the cell and preventing the accumulation of pyrimidine bases, which could otherwise disrupt nucleic acid metabolism and cellular homeostasis.

2.1 Structure and Function

The DPD enzyme is encoded by the DPYD gene, located on chromosome 1p22, spanning approximately 950 kb and comprising 23 exons. The functional protein is a homodimer of ~1025 amino acids per monomer and contains several cofactor-binding domains, including flavin mononucleotide (FMN), flavin adenine dinucleotide (FAD), and iron-sulfur (Fe-S) clusters. These cofactors are crucial for electron transfer during the catalytic reduction of pyrimidine bases.

The catalytic mechanism involves the NADPH-dependent reduction of uracil and thymine to dihydrouracil and dihydrothymine, respectively. This reaction constitutes the first step in a multistep catabolic pathway that ultimately leads to the formation of β-alanine and β-aminoisobutyric acid. Beyond its physiological role in nucleotide degradation, DPD is also the principal enzyme responsible for the inactivation of fluoropyrimidine drugs, including 5-fluorouracil (5-FU), thereby influencing their pharmacokinetics and therapeutic efficacy.

2.2 Regulation of DPD Expression

The expression of DPYD is regulated at multiple levels, including transcriptional, post-transcriptional, and epigenetic mechanisms. Tissue-specific regulation has been observed, with the highest levels of DPD expression in the liver, gastrointestinal mucosa, and peripheral blood mononuclear cells — sites directly involved in drug metabolism. Hormonal signals, cytokines, and nutritional status can also influence DPYD transcription, reflecting the enzyme’s role in metabolic adaptation.

Post-transcriptional regulation by microRNAs (miRNAs), particularly miR-27a, has been reported to modulate DPD levels, linking non-coding RNA activity to chemotherapeutic drug response. Moreover, genetic polymorphisms in regulatory regions of the DPYD gene can lead to altered expression or function, contributing to interindividual variability in DPD activity.

2.3 Clinical Implications of DPD Activity

The central role of DPD in both pyrimidine metabolism and fluoropyrimidine detoxification makes it a key determinant in chemotherapy outcomes. Variations in enzyme activity — whether due to genetic mutations, epigenetic changes, or post-transcriptional regulation — can significantly alter drug exposure and toxicity risk.

3. DPD Deficiency: Genetic and Biochemical Basis

Dihydropyrimidine dehydrogenase deficiency (DPD deficiency) is a pharmacogenetically relevant condition characterized by reduced or absent enzymatic activity of the DPD enzyme, resulting in impaired catabolism of pyrimidines and fluoropyrimidines. Although rare in the general population, DPD deficiency represents a major risk factor for fluoropyrimidine-associated toxicity in oncology patients.

3.1 Types of DPD Deficiency

Complete DPD deficiency: A rare autosomal recessive disorder, often diagnosed in infancy or childhood, characterized by neurological manifestations such as developmental delay, epilepsy, microcephaly, and growth retardation.
Partial DPD deficiency: Far more common in the general population, usually asymptomatic under normal conditions, but clinically significant when patients are exposed to 5-fluorouracil (5-FU), capecitabine, or related drugs. Even a modest reduction in enzyme activity can precipitate severe, life-threatening adverse drug reactions.

3.2 Genetic Basis: DPYD Mutations

The DPYD gene encodes the DPD enzyme, and pathogenic variants within this gene are the primary cause of DPD deficiency. To date, more than 160 DPYD variants have been identified, but only a subset is known to have strong clinical significance.

The most frequently studied variants include:

c.1905+1G>A (DPYD*2A) – a splice-site mutation leading to loss of function.
c.1679T>G (DPYD*13) – associated with complete loss of enzymatic activity.
c.2846A>T – linked to partial deficiency and high risk of 5-FU toxicity.
c.1236G>A (HapB3 variant) – associated with reduced enzyme activity and increased toxicity risk.

These variants exhibit variable allele frequencies across populations, underlining the importance of population-specific pharmacogenomic studies.

3.3 Biochemical Consequences

In the absence of functional DPD activity, uracil and thymine accumulate in plasma and tissues. This leads to an increased uracil-to-dihydrouracil ratio, which can be measured as a phenotypic biomarker of DPD deficiency. In oncology patients, impaired DPD activity prevents the effective detoxification of fluoropyrimidines, causing excessive systemic exposure to active metabolites.

Clinically, this manifests as:

Hematological toxicity (neutropenia, anemia, thrombocytopenia)
Gastrointestinal toxicity (mucositis, diarrhea, nausea, vomiting)
Neurotoxicity (ataxia, seizures, encephalopathy in severe cases)
Dermatological effects (hand-foot syndrome with capecitabine)

3.4 Epidemiology

It is estimated that 3–5% of the general population carry clinically significant DPYD variants leading to partial DPD deficiency. Complete deficiency is much rarer, with prevalence estimated at 1 in 10,000 to 1 in 50,000 individuals. Importantly, the prevalence of actionable variants differs by ethnicity, reinforcing the need for pharmacogenomic screening prior to fluoropyrimidine therapy.

4. Clinical Relevance of DPD Deficiency

Dihydropyrimidine dehydrogenase deficiency (DPD deficiency) has major implications in clinical oncology, particularly in the context of fluoropyrimidine-based chemotherapy. Since 5-fluorouracil (5-FU), capecitabine, and tegafur are widely used for the treatment of solid tumors, including colorectal, breast, gastric, and head and neck cancers, variability in DPD activity is a crucial determinant of treatment outcomes and patient safety.

4.1 Fluoropyrimidine Toxicity and DPD Deficiency

In patients with partial or complete DPD deficiency, standard doses of fluoropyrimidines can lead to severe, sometimes fatal, toxicity due to impaired drug catabolism. As more than 80% of 5-FU is normally inactivated by DPD, reduced activity results in elevated systemic exposure to the active drug and its metabolites.

Clinical manifestations of toxicity include:

Hematological complications: profound neutropenia, leukopenia, anemia, thrombocytopenia.
Gastrointestinal toxicity: mucositis, severe diarrhea, nausea, vomiting.
Neurological effects: ataxia, encephalopathy, seizures in rare cases.
Dermatological manifestations: hand-foot syndrome (palmar-plantar erythrodysesthesia).

These toxicities not only compromise quality of life but can also necessitate treatment discontinuation, delay in cancer therapy, and increased mortality risk.

4.2 Clinical Case Evidence

Numerous case reports and clinical studies have documented life-threatening toxicities in patients with unrecognized DPD deficiency treated with standard doses of fluoropyrimidines. In some series, severe toxicity has been observed in up to 30–50% of carriers of deleterious DPYD variants, underscoring the importance of pre-treatment screening.

4.3 Implications for Cancer Treatment

Dose adjustments: Patients with partial deficiency may tolerate reduced fluoropyrimidine doses, while those with complete deficiency should generally avoid these agents.
Alternative therapies: In cases of complete deficiency, non-fluoropyrimidine regimens or targeted therapies should be considered.
Survival outcomes: Avoiding severe toxicity through genotype- or phenotype-guided therapy can improve adherence to chemotherapy protocols and overall survival.

4.4 Broader Relevance Beyond Oncology

Although primarily studied in the context of chemotherapy, DPD deficiency also contributes to rare inborn errors of metabolism. Complete deficiency may present in childhood with developmental delay, epilepsy, and neurological symptoms, independent of drug exposure. These cases highlight the broader role of DPD in pyrimidine metabolism and neurological function.

5. Diagnostic and Screening Approaches

Because dihydropyrimidine dehydrogenase (DPD) deficiency is a major predictor of fluoropyrimidine-related toxicity, early identification of at-risk patients is essential before initiating chemotherapy with 5-fluorouracil (5-FU), capecitabine, or tegafur. Screening strategies rely on both genotypic and phenotypic testing, each with distinct advantages and limitations.

5.1 Genetic Testing (DPYD Genotyping)

Genetic screening focuses on identifying clinically relevant variants in the DPYD gene. The most commonly tested variants include:

DPYD*2A (c.1905+1G>A) – splice-site mutation leading to nonfunctional protein.
DPYD*13 (c.1679T>G) – severe loss-of-function variant.
c.2846A>T – associated with reduced enzyme activity.
HapB3 (c.1236G>A in linkage with c.1129–5923C>G) – moderate risk allele.

These variants are incorporated into international pharmacogenomic guidelines (e.g., CPIC, EMA) as actionable markers. Patients carrying high-risk alleles may require dose reductions or alternative therapies.

Strengths:

Predictive of well-characterized risk alleles.
Increasingly available in clinical oncology settings.
Provides permanent patient-specific pharmacogenomic information.

Limitations:

Only a subset of pathogenic variants is routinely tested.
Does not account for rare or novel mutations.
Genotype does not always perfectly correlate with enzyme activity.

5.2 Phenotypic Testing (Enzyme Activity and Uracil Levels)

Phenotyping assesses actual DPD activity rather than genetic predisposition. Two major approaches are used:

Plasma uracil concentration: Elevated pre-treatment plasma uracil levels (>16 ng/mL) indicate reduced DPD activity.
Uracil/dihydrouracil ratio: A more precise measure of enzymatic activity, as it reflects both substrate and product concentrations.

Strengths:

Directly measures functional enzyme activity.
Detects deficiencies caused by rare or unknown mutations.

Limitations:

Influenced by external factors (nutrition, hepatic function, circadian variation).
Requires specialized analytical methods (e.g., LC-MS/MS).

5.3 Clinical Guidelines and Implementation

The European Medicines Agency (EMA) recommends pre-treatment DPD testing (genotyping or phenotyping) before starting fluoropyrimidines.
The Clinical Pharmacogenetics Implementation Consortium (CPIC) provides detailed dosing guidelines based on DPYD genotype.
The FDA has included warnings about DPD deficiency in drug labels but has not mandated universal testing.

Implementation in routine practice is increasing, particularly in Europe, where prospective screening has been shown to reduce severe toxicity rates without compromising efficacy.

5.4 Combined Approaches and Future Directions

Given the limitations of single-method testing, combined genotypic and phenotypic screening is emerging as the optimal strategy. Integration of next-generation sequencing (NGS), liquid biopsy, and machine learning-based risk prediction models may further refine screening and allow fully personalized dosing strategies.

6. Pharmacogenomics and Personalized Medicine

The study of dihydropyrimidine dehydrogenase (DPD) exemplifies the growing role of pharmacogenomics in tailoring cancer treatment. Because DPD is responsible for the catabolism of more than 80% of administered 5-fluorouracil (5-FU), interindividual variation in DPYD gene function has a direct impact on drug exposure, toxicity, and therapeutic outcomes. Incorporating DPD testing into clinical practice is therefore central to the development of personalized medicine in oncology.

6.1 Pharmacogenetic Guidelines

Several expert bodies have developed evidence-based recommendations for adjusting fluoropyrimidine dosing according to DPYD genotype:

Clinical Pharmacogenetics Implementation Consortium (CPIC): Provides dosing algorithms for commonly tested DPYD variants.
Dutch Pharmacogenetics Working Group (DPWG): Recommends dose reductions or alternative therapies depending on variant type.
European Medicines Agency (EMA): Advocates routine DPD testing before starting fluoropyrimidine-based chemotherapy.
FDA: Includes warnings in drug labeling, although universal testing is not yet mandated in the United States.

6.2 Dose Adjustment Strategies

Patients are stratified based on DPYD metabolizer status:

Normal metabolizers (wild-type DPYD): Standard dosing of 5-FU, capecitabine, or tegafur.
Intermediate metabolizers (heterozygous for reduced-function variants): Recommended dose reduction (25–50%), followed by careful titration.
Poor metabolizers (homozygous for loss-of-function variants): Fluoropyrimidines contraindicated; alternative regimens preferred.

This genotype-guided dosing strategy minimizes toxicity while preserving antitumor efficacy.

6.3 Clinical Benefits of Personalized Therapy

Reduced toxicity risk: Early screening significantly lowers rates of severe adverse events, including life-threatening myelosuppression and neurotoxicity.
Optimized efficacy: Avoiding dose-limiting toxicities allows patients to maintain therapy, improving treatment adherence and outcomes.
Cost-effectiveness: Pharmacogenomic testing reduces hospitalization costs linked to chemotherapy complications.
Patient safety and quality of life: Preemptive identification of high-risk individuals enhances supportive care planning.

6.4 Emerging Biomarkers and Research Directions

Although current clinical practice primarily focuses on a handful of DPYD variants, ongoing research is expanding the pharmacogenomic landscape:

Rare DPYD mutations: Whole-exome and next-generation sequencing are uncovering novel variants with potential clinical relevance.
Multi-omic approaches: Integration of genomic, transcriptomic, and metabolomic data may improve prediction of fluoropyrimidine response.
MicroRNA regulation: Post-transcriptional modulators such as miR-27a are being investigated as biomarkers of DPD expression and activity.
Artificial intelligence models: Machine learning may help combine genetic, phenotypic, and clinical data to generate individualized dosing recommendations.

Conclusion

Dihydropyrimidine dehydrogenase (DPD) plays a central role in pyrimidine catabolism and the metabolism of fluoropyrimidine chemotherapeutics. Variability in DPYD gene function directly influences drug toxicity and treatment outcomes, making DPD deficiency a critical factor in oncology. Advances in genetic and phenotypic testing have enabled the integration of pharmacogenomics into clinical practice, allowing for safer and more effective use of 5-FU, capecitabine, and related agents. As research continues to uncover novel biomarkers and regulatory mechanisms, personalized medicine strategies will further refine cancer therapy, ensuring both efficacy and patient safety.